Homozygous familial hypercholesterolaemia: update on management

24Citations
Citations of this article
65Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Homozygous familial hypercholesterolaemia (HoFH) is an inherited disease causing an approximately fourfold increase in blood low-density lipoprotein cholesterol (LDLC) from birth compared with the age-matched normal population owing to reduced low-density lipoprotein receptor (LDLR) activity. Such elevated cholesterol is associated with accelerated atheromatous disease, particularly of the aortic root and coronary arteries. However, HoFH is clinically heterogeneous, reflecting residual low-density lipoprotein receptor (LDLR) activity. The main objective in treating children may be stated to be the avoidance of irreversible cardiac damage requiring heart transplantation by sufficient lowering of blood cholesterol. Lipoprotein apheresis or plasmapheresis are safe means of lowering cholesterol but may be insufficient on their own. Statin drugs, PCSK9 inhibitors ezetimibe and bile acid sequestrants are relatively ineffective if LDLR activity is lacking, but should be used if effective. Two new drugs, lomitapide and mipomersen, have been licensed specifically for HoFH by some regulatory authorities. They work by reducing LDL production rate. They have been associated with fatty liver in adults. Evidence of safety in children is lacking. An alternative is liver transplantation, which replaces the missing LDLR and normalises cholesterol. Clinicians are faced with a dilemma in choosing between these options or deferring such treatment associated with potential harm. Individual case descriptions are an important means of informing clinical judgement. Management of the two cases described in this issue is discussed in the light of modern developments in transplantation and pharmacotherapy.

References Powered by Scopus

The LDL receptor

1039Citations
N/AReaders
Get full text

Homozygous familial hypercholesterolaemia: New insights and guidance for clinicians to improve detection and clinical management. A position paper fromthe Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society

892Citations
N/AReaders
Get full text

LOVD v.2.0: The next generation in gene variant databases

843Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Functional analysis of LDLR (low-density lipoprotein receptor) variants in patient lymphocytes to assess the effect of evinacumab in homozygous familial hypercholesterolemia patients with a spectrum of LDLR activity

71Citations
N/AReaders
Get full text

Familial hypercholesterolemia: New horizons for diagnosis and effective management

39Citations
N/AReaders
Get full text

Recent advances in targeted delivery of non-coding RNA-based therapeutics for atherosclerosis

34Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

France, M. (2016, October 1). Homozygous familial hypercholesterolaemia: update on management. Paediatrics and International Child Health. Taylor and Francis Ltd. https://doi.org/10.1080/20469047.2016.1246640

Readers over time

‘16‘17‘18‘19‘20‘21‘22‘23‘24‘250481216

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 12

57%

Researcher 7

33%

Professor / Associate Prof. 2

10%

Readers' Discipline

Tooltip

Medicine and Dentistry 19

66%

Pharmacology, Toxicology and Pharmaceut... 5

17%

Agricultural and Biological Sciences 3

10%

Biochemistry, Genetics and Molecular Bi... 2

7%

Save time finding and organizing research with Mendeley

Sign up for free
0